Loading...
Derniers dépôts
-
Ketsia Bakambamba. Identification des acteurs moléculaires régulés par IRE1 qui contrôlent la sécrétion de protéines dans les cellules de glioblastome1 that control protein secretion in glioblastoma cells. Human health and pathology. Université de Rennes, 2024. English. ⟨NNT : 2024URENB027⟩. ⟨tel-04960700⟩
-
-
-
Jerome Lorenzini, Flavie Arbion, Cyril Touboul, Yohann Dabi, Yohan Kerbage, et al.. Association between treatment center volume and survival of endometrial cancer patients: A multicenter study: A Francogyn group study. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2025, 306, pp.194-198. ⟨10.1016/j.ejogrb.2025.01.001⟩. ⟨hal-04927369⟩
-
-
-
-
-
-
-
Sarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabró, Gino Philips, Ugne Balaseviciute, et al.. Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma. Journal of Hepatology, In press, ⟨10.1016/j.jhep.2024.12.016⟩. ⟨hal-04867696⟩
-
Marnix Lam, Etienne Garin, Paul Haste, Alban Denys, Brian Geller, et al.. Utility of pre-procedural [(99m)Tc]TcMAA SPECT/CT Multicompartment Dosimetry for Treatment Planning of (90)Y Glass microspheres in patients with Hepatocellular Carcinoma: comparison of anatomic versus [(99m)Tc]TcMAA-based Segmentation. European Journal of Nuclear Medicine and Molecular Imaging, 2024, Online ahead of print. ⟨10.1007/s00259-024-06920-6⟩. ⟨hal-04846280⟩
-
Lucille Vitek, Thomas Goronflot, Caroline Dutriaux, Antoine Deleuze, Yannick Le Corre, et al.. Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study. Acta Dermato-Venereologica, 2024, 104, pp.adv41297. ⟨10.2340/actadv.v104.41297⟩. ⟨inserm-04839709⟩
-
-
Aurélie Gouel-Cheron, Ludovic Meuret, Hélène Beloeil, Raphaël Cinotti, Maxime Léger. Motivations and barriers to clinical research participation among anaesthesiology and intensive care staff in France [Letter]. Anaesthesia Critical Care & Pain Medicine, 2024, 43 (6), pp.101442. ⟨10.1016/j.accpm.2024.101442⟩. ⟨hal-04765903⟩
-
Ingrid Masson, Laurène Larriviere, Marc-André Mahé, David Azria, Pascal Pommier, et al.. Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer. Clinical and Translational Radiation Oncology, 2024, 44, pp.100702. ⟨10.1016/j.ctro.2023.100702⟩. ⟨hal-04813716⟩
-
Jennifer Le Guévelou, Thomas Zilli, Ludovic Ferretti, Luc Beuzit, Olivier de Hertogh, et al.. Urinary Organs at Risk for Prostate Cancer External Beam Radiation Therapy : Contouring Guidelines on Behalf of the Francophone Group of Urological Radiation Therapy. Practical Radiation Oncology: An official journal of the American Society for Radiation Oncology, 2024, 14 (6), pp.541-554. ⟨10.1016/j.prro.2024.05.009⟩. ⟨hal-04812312⟩
-
Sylvain Manfredi, Anthony Turpin, David Malka, Emilie Barbier, Pierre Laurent-Puig, et al.. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study. Digestive and Liver Disease, 2020, 52 (10), pp.1143-1147. ⟨10.1016/j.dld.2020.06.034⟩. ⟨hal-04548048⟩
-
Sarah Atallah, Odile Casiraghi, Nicolas Fakhry, Michel Wassef, Emmanuelle Uro-Coste, et al.. A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma: epidemiology and prognostic factors. European journal of cancer, 2020, 130, pp.241-249. ⟨10.1016/j.ejca.2020.01.023⟩. ⟨hal-03599053⟩
-